Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future
Bernstein said Novartis' decision to discontinue VHB937 for amyotrophic lateral sclerosis (ALS) on September 16 improves the commercial landscape for Zydus Lifesciences' Usnoflast.
\